Abstract: Breast cancer is the most common tumor worldwide with a good overall prognosis. However, some patients still endure tumor progression after surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy. For patients with progressive disease, immunotherapy has become an alternative treatment option. As one of the main immunotherapeutic approaches, the application of immune checkpoint inhibitors(ICIs)in breast cancer treatment continues to expand, providing new options for neoadjuvant treatment, and neoadjuvant treatment improves breast conservation rates. It has important clinical significance in evaluating therapeutic efficacy, and guiding individualized treatment. This article will review the current clinical research progress of ICIs in the neoadjuvant treatment of various subtypes of early breast cancer.

Key words: Breast cancer, Immune checkpoint inhibitors, Neoadjuvant therapy, Immunotherapy